Video - Results from #30

AUA 2022 VL

Search

Prostate Volume, Baseline Urinary Symptoms, and Their Association with Treatment Choice and Post-Treatment Urinary Function in Men with Localized Prostate Cancer, The CEASAR Study - Daniel Barocas Details Daniel Barocas joins Alicia Morgans in a conversation on the prospective population-based Comparative Effectiveness Analysis of Surgery And Radiation (CEASAR) study which assess rates and predictors of patient-reported treatment regret among men deciding on treatment for localized prostate cancer. The CEASAR Study began accruing patients in 2010 and has a population-based cohort of almost 3000 men...
Early Triplet Combination Therapy Shows Increased Overall Survival: The ARASENS Trial - Tomasz Beer Details Alicia Morgans is joined by Tomasz Beer for a discussion on the ARASENS trial. Recently presented at GU ASCO 2022, the ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC) and ECOG performance status 0 or 1. The most important finding was androgen deprivation therapy (ADT) plus docetaxel plus darolutamide pr...
New Orleans Restaurant Favorites - Plan Your AUA 2022 Dining Experiences - Oliver Sartor Details Drs Oliver Sartor and Phillip Koo explore the New Orleans restaurant scene in advance of the 2022 American Urological Association (AUA) annual meeting that takes place May 13-16. The 2022 meeting is the 117th meeting, providing unparalleled access to groundbreaking research, new guidelines, and the latest advances in urologic medicine. In this short video, Drs. Sartor and Koo provide you with all...
Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore Details Fred Saad, Bertrand Tombal, and Neal Shore join Alicia Morgans in a discussion on the results of the ARASENS trial which examined darolutamide in combination with docetaxel and ADT compared to docetaxel and ADT. They discuss the trial design, its endpoints, how it impacts practice in Canada, the US, and in Europe, and the ideal patient population for this treatment. Biographies: Neal Shore, MD, FA...
ARASENS Trial Significantly Improves Overall Survival with Darolutamide in Combination with ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith Details Joining Alicia Morgans is Matthew Smith to discuss the ARASENS trial presented at GU ASCO 2022. ARASENS is a randomized phase 3 trial of darolutamide versus placebo in combination with docetaxel and androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Smith believes that the ARASENS data strongly supports a three-drug regimen of ADT, docetaxel, and an AR...
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi Details Karim Fizazi joins Alicia Morgans in discussing the ARASENS trial which examined darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1. Drs. Morgans and Fizazi detail the overall survival data presented at...